The year in charts

The year in charts

Tuesday, April 21, 2020 @ 10:00 am

Number of Biotech Companies in Switzerland 2009-2019

Number of Swiss Biotech Employees 2017-2019

Capital investments in Swiss biotech companies

Private & Public Swiss Biotech Companies

Revenues, R&D expenses, Profit/loss, Liquidity

Total Swiss Biotech Companies

Revenues, R&D expenses, Profit/loss, Liquidity

Public Swiss Biotech Companies

Revenues, R&D expenses, Profit/loss, Liquidity

Private Swiss Biotech Companies

Tags

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Umlaut.bio: Prestigious funding by BaseLaunch and strengthing scientific advisory board

BaseLaunch selects Umlaut.bio for support thereby raising the pre-seed funding to a total of ~EUR 3m Prof. Dr. Oliver Distler, Universitätspital Zurich, joins Umlaut.bio’s SAB catalyzing the development of the systemic sclerosis franchise Prof. Dr. Tsutomu Suzuki, University Tokio, completes the SAB, underpinning the worldwide leadership in tRNA science
February 19, 2026

NewBiologix: Publication validates platform for high-quality rAAV production

NewBiologix S.A., a biotechnology company advancing recombinant adeno-associated virus (rAAV) production through next-generation clonal HEK293 cell line technology, today announced publication of peer-reviewed data in Biotechnology Reports (Vol. 49, March 2026). Paper reports two-fold higher full-to-empty rAAV ratio using NBX1P01 compared to a leading commercial HEK293 cell line.
February 18, 2026

leadXpro and Nuclera partner for complex membrane proteins

Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform structure-based drug design
February 17, 2026

InSphero and PharmaNest: Partnership to advance translational fibrosis research

InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems signed a partnership with PharmaNest Inc, a Princeton, NJ-based digital pathology company.
February 11, 2026

Industry leaders form alliance for microphysiological systems

A new united voice for a strategic sector for Europe
February 10, 2026